Robert Jr. Baltera Buys 20,000 Shares of Palisade Bio (NASDAQ:PALI) Stock

Palisade Bio, Inc. (NASDAQ:PALI) Director Robert Jr. Baltera bought 20,000 shares of Palisade Bio stock in a transaction that occurred on Wednesday, July 1st. The shares were acquired at an average cost of $1.98 per share, for a total transaction of $39,600.00. Following the acquisition, the director owned 356,904 shares in the company, valued at $706,669.92. The trade was a 5.94% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Robert Jr. Baltera also recently made the following trade(s):

• On Thursday, July 2nd, Robert Jr. Baltera purchased 10,000 shares of Palisade Bio stock. The shares were acquired at an average price of $1.98 per share, with a total value of $19,800.00.

Palisade Bio Trading Up 2.0%

PALI opened at $2.08 on Wednesday. The company has a market cap of $361.05 million, a P/E ratio of -2.06 and a beta of 1.50. The business’s 50-day moving average price is $1.91 and its 200-day moving average price is $1.92. Palisade Bio, Inc. has a 12 month low of $0.53 and a 12 month high of $2.86.

Palisade Bio (NASDAQ:PALI) last issued its earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Equities research analysts forecast that Palisade Bio, Inc. will post -0.25 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in PALI. Perceptive Advisors LLC purchased a new stake in shares of Palisade Bio in the 4th quarter worth about $28,318,000. Commodore Capital LP purchased a new position in shares of Palisade Bio during the fourth quarter valued at about $26,896,000. Janus Henderson Group PLC purchased a new position in shares of Palisade Bio during the fourth quarter valued at about $24,822,000. RA Capital Management L.P. bought a new position in Palisade Bio in the fourth quarter worth about $16,742,000. Finally, Eversept Partners LP purchased a new stake in Palisade Bio in the fourth quarter worth about $12,670,000. 11.79% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

PALI has been the topic of several analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $2.00 target price on shares of Palisade Bio in a research note on Tuesday, June 30th. Weiss Ratings raised shares of Palisade Bio from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 29th. LADENBURG THALM/SH SH upgraded shares of Palisade Bio to a “strong-buy” rating in a research report on Thursday, June 25th. Wall Street Zen raised shares of Palisade Bio from a “sell” rating to a “hold” rating in a research note on Sunday. Finally, Oppenheimer set a $7.00 target price on shares of Palisade Bio in a report on Tuesday, June 30th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Palisade Bio presently has a consensus rating of “Buy” and a consensus target price of $8.83.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.